EUVIMEDEUVIMED entdecken
Crossref

Clinical Characteristics of Users of Weight Loss Drugs: Population‐Based Case–Control Study

Inger Johanne Bakken iD, Paz Lopez-Doriga Ruiz iD, Kari Furu iD, Hanne L Gulseth iD, Kari Anne Sveen iD, Kjersti Nøkleby iD, Haakon E Meyer iD, Lars J Kjerpeseth iD, Øystein Karlstad iD

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6312-6323

DOI: 10.1111/dom.70827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 05.05.2026. Verfasst von Inger Johanne Bakken und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the clinical characteristics of weight loss drugs (WLDs) users in Norway.

Design

Nested population‐based case–control study.

Setting

Nationwide healthcare registries with data on dispensed medications and healthcare diagnoses.

Participants

Individuals aged 18–74 years initiating WLDs during 2023–2024, categorised by drugs: semaglutide (only Wegovy), liraglutide (only Saxenda), tirzepatide, bupropion‐naltrexone or orlistat. Each WLD user was matched with five age‐ and sex‐matched population controls. Main Outcome Measures Comorbidities diagnosed in the 2 years preceding initiation of WLD use and comedications dispensed in the preceding year, analysed using conditional logistic regression.

Results

150 036 individuals initiated semaglutide, 4603 liraglutide, 3596 tirzepatide, 31 172 bupropion–naltrexone and 1411 orlistat. Among WLD users, 71%–78% were registered with at least one comorbidity, compared with 49%–51% in controls. Nineteen percent to 24% of WLD users had four or more comorbidities. Hypertension was observed among 32%–38% of WLD users versus 17%–20% of controls; hyperlipidaemias: 20%–24% versus 12%–15%; sleep apnoea: 7%–11% versus 2%–3%; back pain: 15%–20% versus 10%–11%; opioids: 24%–30% versus 13%–15%; antidepressants: 20%–24% versus 10%–11%. Having only a basic level of education (≤ 10 years) was more common among WLD users than among controls (20%–28% vs. 17%), except for tirzepatide users, where the education level distribution was as for controls.

Conclusions

WLD use is rapidly increasing, with users often having complex comorbidities. Understanding these patterns helps ensure that medications are used as intended. Like other countries with universal health systems, Norway must address the high cost of obesity treatments and mitigate health disparities to ensure access for those most likely to benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityGlucagon-Like Peptide-1 Receptor AgonistsAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultBupropionCase-Control StudiesComorbidityLiraglutideNaltrexoneNorwayOrlistatRegistriesSemaglutideTirzepatideWeight LossDrug Combinations

Stichwörter der Autor:innen

Bupropioncomorbidityliraglutidemultimorbiditynaltrexoneobesityorlistatsemaglutidetirzepatideweight‐loss

Substanzen

Anti-Obesity AgentsBupropionbupropion hydrochloride, naltrexone hydrochoride drug combinationLiraglutideNaltrexoneOrlistatSemaglutideTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsDrug Combinations

Autor:innen und Institutionen

  • Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
  • Institute of Health, Oslo New University College, Oslo, Norway.
  • Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Division of Public Health and Prevention, Norwegian Institute of Public Health, Oslo, Norway.
  • Department of Health Registry Research and Development, Norwegian Institute of Public Health, Oslo, Norway.
  • Department of Endocrinology, Preventive Medicine and Morbid Obesity, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Inger Johanne Bakken, Paz Lopez-Doriga Ruiz, Kari Furu, Hanne L Gulseth, Kari Anne Sveen, Kjersti Nøkleby, Haakon E Meyer, Lars J Kjerpeseth, Øystein Karlstad

Zitieren

APA

Bakken, I. J., Ruiz, P. L., Furu, K., Gulseth, H. L., Sveen, K. A., Nøkleby, K., Meyer, H. E., Kjerpeseth, L. J., & Karlstad, Ø. (2026). Clinical Characteristics of Users of Weight Loss Drugs: Population‐Based Case–Control Study. Diabetes, Obesity and Metabolism, 28(7), 6312-6323. https://doi.org/10.1111/dom.70827

Vancouver

Bakken IJ, Ruiz PL, Furu K, Gulseth HL, Sveen KA, Nøkleby K, et al. Clinical Characteristics of Users of Weight Loss Drugs: Population‐Based Case–Control Study. Diabetes, Obesity and Metabolism. 2026;28(7):6312-6323. doi:10.1111/dom.70827

BibTeX
@article{Bakken2026,
  author = {Bakken, Inger Johanne and Ruiz, Paz Lopez-Doriga and Furu, Kari and Gulseth, Hanne L and Sveen, Kari Anne and Nøkleby, Kjersti and Meyer, Haakon E and Kjerpeseth, Lars J and Karlstad, Øystein},
  title = {Clinical Characteristics of Users of Weight Loss Drugs: Population‐Based Case–Control Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {6312--6323},
  doi = {10.1111/dom.70827}
}
Kostenlos starten →